Status:
COMPLETED
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
Lead Sponsor:
University Hospital, Ghent
Conditions:
Infectious Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Piperacillin-tazobactam is an acylureido-penicillin-beta-lactamase inhibitor combination and is frequently used in the empirical treatment of hospital-acquired infections because of its antipseudomona...
Eligibility Criteria
Inclusion
- Adult patients (\> 18 years) admitted on the intensive care unit (surgical and medical surgery).
- Starting a treatment with piperacillin/tazobactam
- Signed informed consent
- Hematocrit \>= 21%
- Available arterial line
Exclusion
- age \<18 or \>75 years
- patient's weight \<50 or \>100 kg
- renal insufficiency (estimated clearance \< 50 ML /MIN)
- haemodialysis
- WBC \< 1000 103 µl
- estimated survival \<5 days
- meningitis or other proven infections of the CNS
- IgE-mediated allergy to penicillins
- pregnancy
- patients having participated in another study \<30 days before inclusion in the present study
- retrospectively, marked deterioration of the renal function during the study period
- retrospectively, treatment \< 96 h
Key Trial Info
Start Date :
September 23 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 3 2018
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01198925
Start Date
September 23 2010
End Date
May 3 2018
Last Update
May 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, Belgium